Manejo fisioterapéutico de un paciente con esclerosis lateral amiotrófica

Marcos  Perez-Chuquimia

doi:10.52428/20756208.v18i45.977

Authors

Marcos Perez-Chuquimia Universidad Privada del Valle

DOI:

https://doi.org/10.52428/20756208.v18i45.977

Keywords:

Enfermedad Neurodegenerativa, Esclerosis Amiotrófica Lateral, Apoyo en el Sistema Musculoesquelético

Abstract

The Amyotrophic Lateral Sclerosis disease is considered one of the most common diseases in our environment today, in turn it is one of the most tragic for patients who suffer from it, in addition to their family and social environment in general. This neurodegenerative disease does not show a clearly studied and defined etiology, despite its unknown origin, the worldwide prevalence is still too high, varying between 2 and 11 cases per 100,000 people; The approximate age of presentation is from 58 to 63 years for the less frequent cases, and from 47 to 52 years for the most frequent cases. Knowing one more proposal for physiotherapeutic treatment is of vital importance.

Downloads

Download data is not yet available.

References

Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011 Oct;7(11):639-49. DOI 10.1038/nrneurol.2011.153

https://doi.org/10.1038/nrneurol.2011.153 DOI: https://doi.org/10.1038/nrneurol.2011.153

Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011 Oct;7(11):603-15. DOI 10.1038/nrneurol.2011.150

https://doi.org/10.1038/nrneurol.2011.150 DOI: https://doi.org/10.1038/nrneurol.2011.150

Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009 Sep;73(10):805-11. DOI 10.1212/WNL.0b013e3181b6bbbd.

https://doi.org/10.1212/WNL.0b013e3181b6bbbd DOI: https://doi.org/10.1212/WNL.0b013e3181b6bbbd

D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013 Dec;65:509-27. DOI 10.1016/j.freeradbiomed.2013.06.029.

https://doi.org/10.1016/j.freeradbiomed.2013.06.029 DOI: https://doi.org/10.1016/j.freeradbiomed.2013.06.029

Spreux-Varoquaux O, Bensimon G, Lacomblez L, Salachas F, Pradat PF, Le Forestier N, et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci. 2002 Jan;193(2):73-8. https://doi.org/10.1016/s0022-510x(01)00661-x

https://doi.org/10.1016/S0022-510X(01)00661-X DOI: https://doi.org/10.1016/S0022-510X(01)00661-X

Menzies FM, Ince PG, Shaw PJ. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem Int. 2002 May;40(6):543-51. https://doi.org/10.1016/s0197-0186(01)00125-5

https://doi.org/10.1016/S0197-0186(01)00125-5 DOI: https://doi.org/10.1016/S0197-0186(01)00125-5

Tomkins J, Usher P, Slade JY, Ince PG, Curtis A, Bushby K, et al. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). Neuroreport. 1998 Dec;9 (17):3967-70. https://doi.org/10.1097/00001756-199812010-00036

https://doi.org/10.1097/00001756-199812010-00036 DOI: https://doi.org/10.1097/00001756-199812010-00036

Julien JP. ALS: astrocytes move in as deadly neighbors. Nat Neurosci. 2007 May ;10(5) :535-7. https://doi.org/10.1038/nn0507-535

https://doi.org/10.1038/nn0507-535 DOI: https://doi.org/10.1038/nn0507-535

Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol. 2001 Aug;27(4):257-74. https://doi.org/10.1046/j.0305-1846.2001.00332.x

https://doi.org/10.1046/j.0305-1846.2001.00332.x DOI: https://doi.org/10.1046/j.0305-1846.2001.00332.x

Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry. 2005 Aug;76(8):1046-57. https://doi.org/10.1136%2Fjnnp.2004.048652

https://doi.org/10.1136/jnnp.2004.048652 DOI: https://doi.org/10.1136/jnnp.2004.048652

ELA una enfermedad sin cura y progresiva. Clinica Davila. 2021. https://www.ultimasnoticiasbolivia.com/noticias-belleza-y-salud/ela-una-enfermedad-sin-cura-que-esta-en-bolivia/

Pringle CE, Hudson AJ, Munoz DG, Kiernan JA, Brown WF, Ebers GC. Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria. Brain. 1992 Apr;115 ( Pt 2):495-520. https://doi.org/10.1093/brain/115.2.495

https://doi.org/10.1093/brain/115.2.495 DOI: https://doi.org/10.1093/brain/115.2.495

Ruiz Martinez A, García García JJ. Fisiopatología de la esclerosis lateral amiotrófica. Trabajo de fin de grado. Universidad Zaragoza, Departamento de farmacología y fisiología. 2016. https://pdfslide.tips/documents/fisiopatologa-de-la-esclerosis-lateral-amiotr-3-fisiopatologa-de-la-esclerosis.html?page=1

Perez Akli M, Schiava M, Melcom M. Estudio epidemiológico multicéntrico sobre esclerosis lateral amiotrófica en la Ciudad de Buenos Aires. Neurol arg. 2017 ; 9(4) :225-230. DOI : http://dx.doi.org/10.1016/j.neuarg.2017.07.004

https://doi.org/10.1016/j.neuarg.2017.07.004 DOI: https://doi.org/10.1016/j.neuarg.2017.07.004

Lascurain Vázquez O. Esclerosis lateral amiotrófica (ELA) Enfermedad, tratamiento actual y nuevas estrategias terapéuticas; trabajo de fin de grado. Universidad del País Vasco; facultad de farmacia https://addi.ehu.es/bitstream/handle/10810/54279/TFG_Lascurain.pdf

Seco Calvo J, Sistema Nervioso, Métodos, Fisioterapia Clínica, y Afecciones para Fisioterapeutas, Editorial Medica Panamericana S.A., 2023, agosto.